KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other Non-Current Liabilities (2017 - 2025)

Aquestive Therapeutics has reported Other Non-Current Liabilities over the past 9 years, most recently at $7.3 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $7.3 million for Q4 2025, up 203.51% from a year ago — trailing twelve months through Dec 2025 was $7.3 million (up 203.51% YoY), and the annual figure for FY2025 was $7.3 million, up 203.51%.
  • Other Non-Current Liabilities for Q4 2025 was $7.3 million at Aquestive Therapeutics, up from $2.1 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for AQST hit a ceiling of $7.3 million in Q4 2025 and a floor of $1.8 million in Q1 2021.
  • Median Other Non-Current Liabilities over the past 5 years was $2.0 million (2022), compared with a mean of $2.3 million.
  • Biggest five-year swings in Other Non-Current Liabilities: fell 18.15% in 2022 and later soared 203.51% in 2025.
  • Aquestive Therapeutics' Other Non-Current Liabilities stood at $2.5 million in 2021, then fell by 18.15% to $2.0 million in 2022, then dropped by 0.88% to $2.0 million in 2023, then grew by 18.8% to $2.4 million in 2024, then soared by 203.51% to $7.3 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $7.3 million (Q4 2025), $2.1 million (Q3 2025), and $2.1 million (Q2 2025) per Business Quant data.